MedTrace Logo

Specified Drug-use Surveillance of Fabhalta Capsules

NCT06606314 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a multicenter, single-arm, non-interventional study (NIS) with a central registration system and an all-case surveillance system. The observation period is 48 weeks after the start of treatment with Fabhalta.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
0 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06606314 on ClinicalTrials.gov